Alexion Pharmaceuticals (ALXN) 197.66 $ALXN
3 Growth Stocks In Buy Range After Recent Breakouts
at Investor's Business Daily - Wed Dec 03, 5:41PM CST
Six weeks after the market uptrend was confirmed, many leading stocks are extended from base patterns. However, today's Stock Spotlight features three companies still hovering near recent buy points. NXP Semiconductors (NXPI) is in buy range past a...
ALXN: 197.66 (-1.22), NXPI: 76.14 (-0.71), AVGO: 103.07 (+7.94)
Stock Market Today: Stocks Hold Slim Gains; Alexion Falls
at Investor's Business Daily - Wed Dec 03, 12:24PM CST
Stocks were mildly higher Wednesday afternoon after climbing out of mixed territory earlier. The Nasdaq and the S&P 500 were each up 0.2%. The Dow Jones industrial average lagged with a 0.1% gain. American Express (AXP), Coca-Cola (KO) and Wal-Mart...
AMBA: 55.63 (-0.60), KO: 43.50 (-0.30), AXP: 91.83 (+0.58), ALXN: 197.66 (-1.22), GIII: 96.10 (-0.68), WMT: 84.76 (-0.18), ULTA: 125.74 (+1.06)
Biotech Stock Roundup: Avanir to be Acquired by Japanese Firm, Biogen Scores in Alzheimer's Study - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 03, 9:51AM CST
Although it was a relatively uneventful week, mergers and acquisitions show no signs of slowing down in the biotech sector.
BIIB: 341.18 (-6.16), AVNR: 16.96 (+0.04), VRTX: 118.71 (-1.47), INCY: 74.12 (-0.54), ALXN: 197.66 (-1.22), PBYI: 195.55 (-2.12), REGN: 423.21 (-1.20)
Stock Market News for December 03, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 9:10AM CST
Benchmarks ended in the green as healthcare and energy shares rallied on Tuesday to post solid gains
BIIB: 341.18 (-6.16), ABT: 45.49 (-0.19), CY: 12.48 (-0.03), F: 15.81 (-0.20), VRTX: 118.71 (-1.47), XOM: 94.37 (-0.58), TM: 128.60 (+0.89), AVNR: 16.96 (+0.04), ALXN: 197.66 (-1.22), EOG: 93.00 (+1.20), GM: 33.09 (-0.55), MRO: 29.84 (-0.69), HMC: 31.21 (+0.23), CVX: 112.28 (-1.43), REGN: 423.21 (-1.20), CODE: 29.01 (+0.15)
Meet 5 Big Caps Whose Earnings Are Expected To Surge
at Investor's Business Daily - Wed Dec 03, 7:02AM CST
With the market in a confirmed uptrend, large highly rated companies are steaming full power ahead. Today's Screen Of The Day is Big Cap Leaders, companies with top-notch fundamentals with a market capitalization of at least $10 billion. The list...
GPRO: 71.98 (-1.67), GE: 26.09 (-0.29), SWKS: 69.75 (+3.08), CMG: 663.97 (+12.70), STX: 66.09 (-0.76), ALXN: 197.66 (-1.22), ILMN: 190.83 (-0.42), GM: 33.09 (-0.55), TSM: 22.82 (-0.11), INTC: 37.46 (+0.03), AAPL: 115.49 (-0.44), AVGO: 103.07 (+7.94)
Apple, Facebook: Jason Weiner Of Fidelity's View
at Investor's Business Daily - Tue Dec 02, 5:19PM CST
Jason Weiner is like Green Bay Packers quarterback Aaron Rodgers. Season after season, he keeps performing at a high level. Since Feb. 2, 2007, when Weiner became the signal caller for the now $1.3 billion Fidelity Growth Discovery Fund and its...
AMZN: 316.93 (+0.43), HD: 98.95 (+0.36), FB: 75.24 (+0.36), TRIP: 77.22 (+1.49), ILMN: 190.83 (-0.42), HPQ: 39.07 (+0.02), PCLN: 1,140.11 (+9.94), ORCL: 41.89 (-0.17), EBAY: 54.67 (-0.14), GILD: 101.82 (+0.94), IBM: 164.05 (-0.47), CMG: 663.97 (+12.70), ALXN: 197.66 (-1.22), EXPE: 89.55 (+0.96), LOW: 64.55 (+0.25), GOOGL: 542.58 (+5.61), EMC: 30.32 (+0.01), ULTA: 125.74 (+1.06), SHW: 247.71 (+1.26), MSFT: 48.84 (+0.76), AAPL: 115.49 (-0.44), BABA: 109.17 (-1.47)
Top Funds Gobble Up Tech And Medical Stocks
at Investor's Business Daily - Tue Dec 02, 5:19PM CST
Top stock mutual fund managers in recent months have been feasting on mostly tech and medical stocks, which were among top gainers in November. The nation's leading funds in the past three months have been pouring money into Apple (AAPL), Yahoo...
MNST: 106.61 (-0.35), ACT: 267.50 (+1.66), KR: 60.76 (+2.10), JBLU: 15.09 (+0.27), UAL: 61.75 (+2.46), CELG: 113.63 (-0.60), LUV: 41.39 (+0.34), AGN: 213.71 (+1.74), YHOO: 50.41 (+0.13), DLTR: 69.27 (+0.07), V: 261.14 (-0.46), BIDU: 230.81 (-0.48), SAVE: 83.23 (+1.62), JAZZ: 178.28 (-0.40), ALXN: 197.66 (-1.22), LOW: 64.55 (+0.25), HBI: 111.87 (-2.83), AAPL: 115.49 (-0.44), MA: 88.77 (+0.45), AVGO: 103.07 (+7.94), BABA: 109.17 (-1.47)
SmarTrend Watching for Potential Pullback in Shares of Alexion Pharmaceuticals After 4.30% Gain
Comtex SmarTrend(R) - Tue Dec 02, 3:52PM CST
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $193.07 to a high of $202.04. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high of $196.49 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 197.66 (-1.22)
Stock Market Today: Dow Hits High As Stocks Recover
at Investor's Business Daily - Tue Dec 02, 3:20PM CST
Stocks finished higher Tuesday, with the Dow Jones industrial average reaching a new all-time high after Monday's sharp decline. But volume was lower on both exchanges, according to preliminary data. All three major indexes finished up 0.6% in the...
AMBA: 55.63 (-0.60), CY: 12.48 (-0.03), RCL: 77.46 (-0.36), ALXN: 197.66 (-1.22), HAWK: 36.14 (+0.09), CODE: 29.01 (+0.15)
Some Big Cap 20 Names Holding Up In Monday's Sell-Off
at Investor's Business Daily - Mon Dec 01, 5:58PM CST
Monday's sell-off was brutal for most growth stocks, but much of the Big Cap 20 names held up, finishing with only modest losses, their uptrends still intact. That's what an investor would expect since the Big Cap names are older, more established...
ABC: 91.95 (-0.04), VRX: 144.33 (-0.94), V: 261.14 (-0.46), ALXN: 197.66 (-1.22)
Valeant's Onexton Gel Gets FDA Approval for Acne - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 5:30PM CST
Valeant Pharmaceuticals International, Inc.'s (VRX) Onexton Gel received FDA approval for acne vulgaris (including non-inflammatory comedonal and inflammatory acne).
IPXL: 31.58 (-0.59), VRX: 144.33 (-0.94), SCMP: 13.57 (+0.36), ALXN: 197.66 (-1.22), GSK: 45.89 (-0.82)
Newly Profitable Medivation Riding High On Drug Sales
at Investor's Business Daily - Fri Nov 28, 4:20PM CST
Biopharmaceutical company Medivation (MDVN) recently turned profitable in a big way. The company -- a new entrant to the IBD Stock Spotlight screen -- focuses on developing therapies to treat serious illnesses for which few treatment options exist....
CBPO: 67.92 (-0.39), MDVN: 113.16 (-1.84), ALXN: 197.66 (-1.22), CELG: 113.63 (-0.60)
Alexion's Soliris Gets Final Positive NICE Recommendation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 4:00PM CST
Alexion Pharmaceuticals announced that the NICE has recommended the commissioning of Soliris for atypical hemolytic uremic syndrome patients in England.
BIIB: 341.18 (-6.16), ALXN: 197.66 (-1.22), AMGN: 166.55 (-1.52), AMAG: 40.59 (+1.11)
Uptrend Call Working As Alexion Pharmaceuticals Stock Rises 24.6% (ALXN)
Comtex SmarTrend(R) - Fri Nov 28, 9:45AM CST
SmarTrend identified an Uptrend for Alexion Pharmaceuticals (NASDAQ:ALXN) on April 24th, 2014 at $156.80. In approximately 7 months, Alexion Pharmaceuticals has returned 24.63% as of today's recent price of $195.42.
ALXN: 197.66 (-1.22)
NICE supports the commission of Soliris for aHUS
Seeking Alpha - at Seeking Alpha - Thu Nov 27, 11:11AM CST
ALXN: 197.66 (-1.22)
NICE Issues Final Positive Recommendation for National Commissioning of Soliris(R) (eculizumab) for All Patients with aHUS in England
Business Wire - Thu Nov 27, 3:46AM CST
--- Final Evaluation Determination Includes the Same Conditions Discussed in Draft Recommendation, Including Establishment of an Expert Center and a Robust System to Monitor Patients Receiving Treatment -
ALXN: 197.66 (-1.22)
Alexion's (ALXN) Soliris Gets Orphan Drug Status in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 26, 4:10PM CST
Alexion Pharmaceuticals, Inc. (ALXN) announced that Japan's MHLW has granted Soliris orphan drug designation for the treatment of patients suffering from neuromyelitis optica.
BIIB: 341.18 (-6.16), ALXN: 197.66 (-1.22), AMGN: 166.55 (-1.52), AMAG: 40.59 (+1.11)
UniQure sets price record with Glybera
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 2:33PM CST
BIS: 46.40 (+0.64), QURE: 12.64 (-0.84), BIB: 128.92 (-1.83), ALXN: 197.66 (-1.22), IBB: 306.20 (-2.05)
Alexion Pharmaceuticals awarded MHLW's ODD for Soliris for treating patients with neuromyelitis optica in Japan
M2 - Wed Nov 26, 6:39AM CST
Biopharmaceutical company Alexion Pharmaceuticals (NasdaqGS:ALXN) reported on Tuesday the receipt of Japan's Ministry of Health, Labour and Welfare (MHLW) orphan drug designation (ODD) for Soliris (eculizumab) for treating patients with neuromyelitis optica (NMO), a life-threatening, ultra-rare neurologic disorder.
ALXN: 197.66 (-1.22)
Marina Biotech: A Forgotten And Grossly Undervalued Game Changer
The GeoTeam - Seeking Alpha - Tue Nov 25, 9:30AM CST
Earlier this month, investors witnessed another RNAi stock achieve incredible gains based on very early clinical trial data. The company, Regulus Therapeutics (NASDAQ: RGLS ), published its Hepatitis-C Phase I data from a pool of only 16 patients....
ROSG: 2.30 (-0.37), ISIS: 52.68 (-0.93), DRNA: 10.91 (-0.15), ALNY: 100.07 (+0.15), ARWR: 5.00 (-0.35), SRPT: 15.22 (-0.26), ALXN: 197.66 (-1.22), TKMR: 13.01 (-0.56), RGLS: 17.37 (+0.09)
3 Growth Stocks In Buy Range After Recent Breakouts
at Investor's Business Daily - Wed Dec 03, 5:41PM CST
Six weeks after the market uptrend was confirmed, many leading stocks are extended from base patterns. However, today's Stock Spotlight features three companies still hovering near recent buy points. NXP Semiconductors (NXPI) is in buy range past a...
ALXN: 197.66 (-1.22), NXPI: 76.14 (-0.71), AVGO: 103.07 (+7.94)
Stock Market Today: Stocks Hold Slim Gains; Alexion Falls
at Investor's Business Daily - Wed Dec 03, 12:24PM CST
Stocks were mildly higher Wednesday afternoon after climbing out of mixed territory earlier. The Nasdaq and the S&P 500 were each up 0.2%. The Dow Jones industrial average lagged with a 0.1% gain. American Express (AXP), Coca-Cola (KO) and Wal-Mart...
AMBA: 55.63 (-0.60), KO: 43.50 (-0.30), AXP: 91.83 (+0.58), ALXN: 197.66 (-1.22), GIII: 96.10 (-0.68), WMT: 84.76 (-0.18), ULTA: 125.74 (+1.06)
Biotech Stock Roundup: Avanir to be Acquired by Japanese Firm, Biogen Scores in Alzheimer's Study - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 03, 9:51AM CST
Although it was a relatively uneventful week, mergers and acquisitions show no signs of slowing down in the biotech sector.
BIIB: 341.18 (-6.16), AVNR: 16.96 (+0.04), VRTX: 118.71 (-1.47), INCY: 74.12 (-0.54), ALXN: 197.66 (-1.22), PBYI: 195.55 (-2.12), REGN: 423.21 (-1.20)
Stock Market News for December 03, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 9:10AM CST
Benchmarks ended in the green as healthcare and energy shares rallied on Tuesday to post solid gains
BIIB: 341.18 (-6.16), ABT: 45.49 (-0.19), CY: 12.48 (-0.03), F: 15.81 (-0.20), VRTX: 118.71 (-1.47), XOM: 94.37 (-0.58), TM: 128.60 (+0.89), AVNR: 16.96 (+0.04), ALXN: 197.66 (-1.22), EOG: 93.00 (+1.20), GM: 33.09 (-0.55), MRO: 29.84 (-0.69), HMC: 31.21 (+0.23), CVX: 112.28 (-1.43), REGN: 423.21 (-1.20), CODE: 29.01 (+0.15)
Meet 5 Big Caps Whose Earnings Are Expected To Surge
at Investor's Business Daily - Wed Dec 03, 7:02AM CST
With the market in a confirmed uptrend, large highly rated companies are steaming full power ahead. Today's Screen Of The Day is Big Cap Leaders, companies with top-notch fundamentals with a market capitalization of at least $10 billion. The list...
GPRO: 71.98 (-1.67), GE: 26.09 (-0.29), SWKS: 69.75 (+3.08), CMG: 663.97 (+12.70), STX: 66.09 (-0.76), ALXN: 197.66 (-1.22), ILMN: 190.83 (-0.42), GM: 33.09 (-0.55), TSM: 22.82 (-0.11), INTC: 37.46 (+0.03), AAPL: 115.49 (-0.44), AVGO: 103.07 (+7.94)
Apple, Facebook: Jason Weiner Of Fidelity's View
at Investor's Business Daily - Tue Dec 02, 5:19PM CST
Jason Weiner is like Green Bay Packers quarterback Aaron Rodgers. Season after season, he keeps performing at a high level. Since Feb. 2, 2007, when Weiner became the signal caller for the now $1.3 billion Fidelity Growth Discovery Fund and its...
AMZN: 316.93 (+0.43), HD: 98.95 (+0.36), FB: 75.24 (+0.36), TRIP: 77.22 (+1.49), ILMN: 190.83 (-0.42), HPQ: 39.07 (+0.02), PCLN: 1,140.11 (+9.94), ORCL: 41.89 (-0.17), EBAY: 54.67 (-0.14), GILD: 101.82 (+0.94), IBM: 164.05 (-0.47), CMG: 663.97 (+12.70), ALXN: 197.66 (-1.22), EXPE: 89.55 (+0.96), LOW: 64.55 (+0.25), GOOGL: 542.58 (+5.61), EMC: 30.32 (+0.01), ULTA: 125.74 (+1.06), SHW: 247.71 (+1.26), MSFT: 48.84 (+0.76), AAPL: 115.49 (-0.44), BABA: 109.17 (-1.47)
Top Funds Gobble Up Tech And Medical Stocks
at Investor's Business Daily - Tue Dec 02, 5:19PM CST
Top stock mutual fund managers in recent months have been feasting on mostly tech and medical stocks, which were among top gainers in November. The nation's leading funds in the past three months have been pouring money into Apple (AAPL), Yahoo...
MNST: 106.61 (-0.35), ACT: 267.50 (+1.66), KR: 60.76 (+2.10), JBLU: 15.09 (+0.27), UAL: 61.75 (+2.46), CELG: 113.63 (-0.60), LUV: 41.39 (+0.34), AGN: 213.71 (+1.74), YHOO: 50.41 (+0.13), DLTR: 69.27 (+0.07), V: 261.14 (-0.46), BIDU: 230.81 (-0.48), SAVE: 83.23 (+1.62), JAZZ: 178.28 (-0.40), ALXN: 197.66 (-1.22), LOW: 64.55 (+0.25), HBI: 111.87 (-2.83), AAPL: 115.49 (-0.44), MA: 88.77 (+0.45), AVGO: 103.07 (+7.94), BABA: 109.17 (-1.47)
SmarTrend Watching for Potential Pullback in Shares of Alexion Pharmaceuticals After 4.30% Gain
Comtex SmarTrend(R) - Tue Dec 02, 3:52PM CST
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $193.07 to a high of $202.04. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high of $196.49 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 197.66 (-1.22)
Stock Market Today: Dow Hits High As Stocks Recover
at Investor's Business Daily - Tue Dec 02, 3:20PM CST
Stocks finished higher Tuesday, with the Dow Jones industrial average reaching a new all-time high after Monday's sharp decline. But volume was lower on both exchanges, according to preliminary data. All three major indexes finished up 0.6% in the...
AMBA: 55.63 (-0.60), CY: 12.48 (-0.03), RCL: 77.46 (-0.36), ALXN: 197.66 (-1.22), HAWK: 36.14 (+0.09), CODE: 29.01 (+0.15)
Some Big Cap 20 Names Holding Up In Monday's Sell-Off
at Investor's Business Daily - Mon Dec 01, 5:58PM CST
Monday's sell-off was brutal for most growth stocks, but much of the Big Cap 20 names held up, finishing with only modest losses, their uptrends still intact. That's what an investor would expect since the Big Cap names are older, more established...
ABC: 91.95 (-0.04), VRX: 144.33 (-0.94), V: 261.14 (-0.46), ALXN: 197.66 (-1.22)
Valeant's Onexton Gel Gets FDA Approval for Acne - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 5:30PM CST
Valeant Pharmaceuticals International, Inc.'s (VRX) Onexton Gel received FDA approval for acne vulgaris (including non-inflammatory comedonal and inflammatory acne).
IPXL: 31.58 (-0.59), VRX: 144.33 (-0.94), SCMP: 13.57 (+0.36), ALXN: 197.66 (-1.22), GSK: 45.89 (-0.82)
Newly Profitable Medivation Riding High On Drug Sales
at Investor's Business Daily - Fri Nov 28, 4:20PM CST
Biopharmaceutical company Medivation (MDVN) recently turned profitable in a big way. The company -- a new entrant to the IBD Stock Spotlight screen -- focuses on developing therapies to treat serious illnesses for which few treatment options exist....
CBPO: 67.92 (-0.39), MDVN: 113.16 (-1.84), ALXN: 197.66 (-1.22), CELG: 113.63 (-0.60)
Alexion's Soliris Gets Final Positive NICE Recommendation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 4:00PM CST
Alexion Pharmaceuticals announced that the NICE has recommended the commissioning of Soliris for atypical hemolytic uremic syndrome patients in England.
BIIB: 341.18 (-6.16), ALXN: 197.66 (-1.22), AMGN: 166.55 (-1.52), AMAG: 40.59 (+1.11)
Uptrend Call Working As Alexion Pharmaceuticals Stock Rises 24.6% (ALXN)
Comtex SmarTrend(R) - Fri Nov 28, 9:45AM CST
SmarTrend identified an Uptrend for Alexion Pharmaceuticals (NASDAQ:ALXN) on April 24th, 2014 at $156.80. In approximately 7 months, Alexion Pharmaceuticals has returned 24.63% as of today's recent price of $195.42.
ALXN: 197.66 (-1.22)
NICE supports the commission of Soliris for aHUS
Seeking Alpha - at Seeking Alpha - Thu Nov 27, 11:11AM CST
ALXN: 197.66 (-1.22)
NICE Issues Final Positive Recommendation for National Commissioning of Soliris(R) (eculizumab) for All Patients with aHUS in England
Business Wire - Thu Nov 27, 3:46AM CST
--- Final Evaluation Determination Includes the Same Conditions Discussed in Draft Recommendation, Including Establishment of an Expert Center and a Robust System to Monitor Patients Receiving Treatment -
ALXN: 197.66 (-1.22)
Alexion's (ALXN) Soliris Gets Orphan Drug Status in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 26, 4:10PM CST
Alexion Pharmaceuticals, Inc. (ALXN) announced that Japan's MHLW has granted Soliris orphan drug designation for the treatment of patients suffering from neuromyelitis optica.
BIIB: 341.18 (-6.16), ALXN: 197.66 (-1.22), AMGN: 166.55 (-1.52), AMAG: 40.59 (+1.11)
UniQure sets price record with Glybera
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 2:33PM CST
BIS: 46.40 (+0.64), QURE: 12.64 (-0.84), BIB: 128.92 (-1.83), ALXN: 197.66 (-1.22), IBB: 306.20 (-2.05)
Alexion Pharmaceuticals awarded MHLW's ODD for Soliris for treating patients with neuromyelitis optica in Japan
M2 - Wed Nov 26, 6:39AM CST
Biopharmaceutical company Alexion Pharmaceuticals (NasdaqGS:ALXN) reported on Tuesday the receipt of Japan's Ministry of Health, Labour and Welfare (MHLW) orphan drug designation (ODD) for Soliris (eculizumab) for treating patients with neuromyelitis optica (NMO), a life-threatening, ultra-rare neurologic disorder.
ALXN: 197.66 (-1.22)
Marina Biotech: A Forgotten And Grossly Undervalued Game Changer
The GeoTeam - Seeking Alpha - Tue Nov 25, 9:30AM CST
Earlier this month, investors witnessed another RNAi stock achieve incredible gains based on very early clinical trial data. The company, Regulus Therapeutics (NASDAQ: RGLS ), published its Hepatitis-C Phase I data from a pool of only 16 patients....
ROSG: 2.30 (-0.37), ISIS: 52.68 (-0.93), DRNA: 10.91 (-0.15), ALNY: 100.07 (+0.15), ARWR: 5.00 (-0.35), SRPT: 15.22 (-0.26), ALXN: 197.66 (-1.22), TKMR: 13.01 (-0.56), RGLS: 17.37 (+0.09)
